PTX 0.00% 4.3¢ prescient therapeutics limited

Ann: Encouraging data from PTX-200 ovarian cancer trial, page-171

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,656 Posts.
    lightbulb Created with Sketch. 198
    Interesting to see how the ptx200’s progression-free survival data is holding up on the phase 1b Ovarian readout;

    AstraZeneca and Merck & Co. have just had a set back:

    https://www.biopharmadive.com/news/astrazeneca-merck-lynparza-cediranib-ovarian-cancer/574019/
    "Measured by progression-free survival, or the length of time patients live without their tumors getting larger or spreading, the Lynparza-cediranib combination did no better than platinum-based chemotherapy."
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.3¢
Change
0.000(0.00%)
Mkt cap ! $33.82M
Open High Low Value Volume
4.2¢ 4.3¢ 4.2¢ $2.103K 50.07K

Buyers (Bids)

No. Vol. Price($)
2 72361 4.2¢
 

Sellers (Offers)

Price($) Vol. No.
4.3¢ 625714 4
View Market Depth
Last trade - 12.50pm 07/11/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.